Canada markets open in 8 hours 20 minutes
  • S&P/TSX

    18,648.92
    +341.01 (+1.86%)
     
  • S&P 500

    3,719.04
    +71.75 (+1.97%)
     
  • DOW

    29,683.74
    +548.75 (+1.88%)
     
  • CAD/USD

    0.7324
    -0.0026 (-0.36%)
     
  • CRUDE OIL

    81.83
    -0.32 (-0.39%)
     
  • BTC-CAD

    26,724.81
    +964.62 (+3.74%)
     
  • CMC Crypto 200

    446.88
    +18.10 (+4.22%)
     
  • GOLD FUTURES

    1,660.90
    -9.10 (-0.54%)
     
  • RUSSELL 2000

    1,715.24
    +52.73 (+3.17%)
     
  • 10-Yr Bond

    3.7050
    0.0000 (0.00%)
     
  • NASDAQ futures

    11,547.25
    -8.50 (-0.07%)
     
  • VOLATILITY

    30.18
    -2.42 (-7.42%)
     
  • FTSE

    7,005.39
    +20.80 (+0.30%)
     
  • NIKKEI 225

    26,427.36
    +253.38 (+0.97%)
     
  • CAD/EUR

    0.7558
    +0.0011 (+0.15%)
     

Is Andlauer Healthcare Stock a Buy?

·3 min read
healthcare pharma
healthcare pharma

Written by Stephanie Bedard-Chateauneuf, MBA at The Motley Fool Canada

Andlauer Healthcare Group (TSX:AND) hit a 52-week low in June but has since gained almost 33%. Is it time to buy this healthcare stock? Let’s look at Andlauer in more detail to see if it deserves a spot on your buy list.

What does Andlauer do?

Andlauer ships time-sensitive and temperature-controlled healthcare items to different medical facilities and pharmacies in Canada and the United States. The company has an excellent management team that did an excellent job running the business during the pandemic. Andlauer is also quite skilled at making strategic acquisitions, and it is growing its presence in the United States. The company has also demonstrated it is able to generate high profits consistently through various economic cycles.

Andlauer reported strong results for its first quarter

Andlauer released its first-quarter 2022 results on May 4. Management praised its strong financial performance, crediting its acquisitions and organic growth. It achieved 81% growth in its ground transportation product line, higher volume from its existing customer base and improved growth in its air cargo. The company reported revenue growth of 54% to $148 million. Plus, operating profit increased by 45% to $24.2 million. Andlauer reported net income of $16.5 million in Q1 2022, compared to $11.6 million in the prior-year quarter.

The company continued to provide logistics, distribution, specialized transportation and packaging solutions to wholesale and government customers involved in the Canadian supply of COVID-19 vaccines and ancillary products. Some of Andlauer’s peers, like VieMed Healthcare, also received a nice boost in revenue during the pandemic. However, their business will have to undergo a change in order to compensate for this loss of income, as the pandemic is probably mostly behind us. The company’s revenue related to the COVID-19 pandemic represented 5.1% of total revenue in the first quarter of 2022.

EBITDA gained 54% year over year to $39.4 million. The company aims to sustain growth going forward through an aggressive acquisition strategy. In the first quarter of 2022, Andlauer acquired 100% of the issued and outstanding shares of Logistics Support Unit (LSU). This will add the company’s own third-party logistics infrastructure to this company’s impressive holdings.

“We generated strong year-over-year growth in revenue and profitability in both the fourth quarter and full year, reflecting the positive contributions of our acquisitions and continued organic growth,” said Michael Andlauer, chief executive officer of AHG. “The acquisitions we completed during 2021 have significantly enhanced our client service offering and established a strong platform for growth in the U.S. Our recent acquisition of LSU further complements our expanding platform. Looking ahead, we are well positioned to drive continued growth and enhanced shareholder value in 2022 and beyond.”

Andlauer announced a quarterly dividend of $0.06 per share in its Q1 2022 earnings report. That represents a modest yield of 0.5%.

Is this healthcare stock a buy?

Andlauer shares have a favourable price-to-earnings ratio of 20.9. It is trading in attractive value territory relative to its industry peers. Moreover, it is poised for very strong earnings growth in the future. All this make this healthcare stock a buy.

The post Is Andlauer Healthcare Stock a Buy? appeared first on The Motley Fool Canada.

Should You Invest $1,000 In Andlauer Healthcare Group Inc.?

Before you consider Andlauer Healthcare Group Inc., we think you’ll want to hear this.

Our nearly S&P/TSX market doubling* Stock Advisor Canada team just released their top 10 starter stocks for 2022 that we believe could supercharge any portfolio.

Want to see if Andlauer Healthcare Group Inc. made our list? Get started with Stock Advisor Canada today to receive all 10 of our starter stocks, a fully stocked treasure trove of industry reports, two brand-new stock recommendations every month, and much more.

See the 10 Stocks * Returns as of 4/14/22

More reading

Fool contributor Stephanie Bedard-Chateauneuf has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Andlauer Healthcare Group Inc.

2022